Agreement Between Automated and Human Measurements of Heart Rate in Patients With Atrial Fibrillation

Ting-Tse Lin, MD; Chia-Ling Wang, RN; Min-Tsun Liao, MD; Chao-Lun Lai, MD, PhD

Background: The accuracy of heart rate (HR) measurement by automated blood pressure monitors in patients with atrial fibrillation (AF) remains unclear. The authors investigate the agreement between HR measurements by 2 automated devices and human counting in patients with AF. Methods: In 47 patients with persistent AF, HR was recorded using 2 automated blood pressure monitors: Omron M5-i and Microlife BPA100 Plus. Human counting of HR by a stethoscope was used as the reference. For each method, 3 readings were made and the mean was calculated for comparison. In addition to Wilcoxon signed rank test, the correlation between HR measurements by automated devices and human counting was determined using Spearman’s rank correlation coefficient (r), and the agreement between HR measurements by both devices and human counting was validated by the Bland-Altman plot and intraclass correlation coefficient (ICC). Results: Overall, we found no significant difference in HR measurements between devices and human counting (Omron vs human counting, 81.1 ± 11.1 vs 80.2 ± 10.8 beats per minute [bpm]; P = .21, r = 0.911; ICC, 0.954; Microlife vs human counting, 81.3 ± 10.8 vs 80.2 ± 10.8 bpm; P = .22, r = 0.842; ICC, 0.912). However, in patients with HR greater than 80 bpm, the HR measured by the Microlife device was significantly higher than that measured by human counting (91.1 ± 5.2 vs 87.1 ± 8.6 bpm, P = .034). Conclusion: There was a high agreement between HR measurements by 2 automated devices and human counting, but the Microlife device may overestimate HR in AF patients with HR greater than 80 bpm.

KEY WORDS: atrial fibrillation, automated sphygmomanometers heart rate, human counting

Hypertension is the most common risk factor for atrial fibrillation (AF), with a prevalence rate of 1% to 2% in the general population.1,2 Several trials have shown a 60% to 70% prevalence of hypertension in AF population.3,4 The introduction of oscillometric automated blood pressure (BP) monitors has simplified the task of self-monitoring of BP, and has been endorsed by several medical societies.5,6 Commercialized automated oscillometric devices with specific AF-detecting algorithms have sensitivity and specificity of approximately 95% to 97% in recognition of AF.7 The devices show a warning symbol on the screen when the algorithm detects irregular heartbeats, which can be used as a reliable screening instrument for early detection of AF.8–10 The detection of AF could prompt patients to seek medical help for a definite diagnosis of AF. For patients

This work was supported by grant HCH103-022 from the National Taiwan University Hospital Hsin-Chu Branch.
The authors have no conflicts of interest to disclose.

Correspondence
Chao-Lun Lai, MD, PhD, Department of Internal Medicine, National Taiwan University Hospital Hsin-Chu Branch, 25, Ln 442, Section 1, Jingguo Rd, Hsinchu City 30059, Taiwan (chaolunlai@ntu.edu.tw).

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

DOI: 10.1097/JCN.0000000000000486
with hypertension, AF-detecting automated BP monitors may promote daily screening of AF and prompt implementation of strategies for stroke prevention.11

Conventional sphygmomanometers are used to detect Korotkoff sounds to determine systolic and diastolic BPs manually. Automated BP monitors calculate BP by detecting oscillations transmitted from the brachial artery to the cuff.12 Most automated BP monitors are validated and calibrated in subjects in sinus rhythm (SR).13 Although correct measurement of BP may be difficult given the high variability of heart rate (HR) and stroke volume caused by AF,14 many reports showed a high agreement in BP measurements between conventional sphygmomanometers and automated BP monitors in AF patients.14–16 Frequently, automated BP monitors also provide HR measurements. Among patients in SR, the intervals between pulse waves are relatively unchanged and can be used to calculate HR while using automated oscillometric BP monitors. However, the accuracy of HR recorded by automated devices in AF patients is not clear. The present work investigated the accuracy of HR measured by automated oscillometric BP monitors in patients with AF using human counting of heartbeat derived from a stethoscope on the anterior chest as the reference.

Methods

Study Population

We performed a cross-sectional study of 47 patients with persistent AF in a single center. Inclusion criteria were being older than 20 years, presence of AF confirmed by electrocardiography before measurement, and completion of written informed consent for participation. All patients were enrolled in our outpatient clinics and were ambulatory and stable. Exclusion criteria were hemodynamic or respiratory instability, moderate to severe aortic insufficiency, and upper arm circumferences of less than 26 cm or greater than 35 cm. The restriction of upper arm circumstances is in accordance with the American Heart Association recommendation for a standard cuff bladder.5 The study period was from January 1, 2014, to January 31, 2016.

From each patient, we obtained demographic variables such as age; gender; associated comorbidities such as congestive heart failure, coronary artery disease, valvular heart disease, hypertension, peripheral artery disease, diabetes mellitus, stroke, hyperlipidemia, hyperthyroidism, chronic kidney disease, and smoking status; and medications currently used including aspirin, anticoagulants, amiodarone, digoxin, renin-angiotensin system blockers, α-blockers, β-blockers, calcium channel blockers, diuretics, nitrates, oral antidiabetic drugs, and statins. The CHA2DS2-VASc score (congestive heart failure, hypertension, age ≥75 years [2 points], diabetes, stroke [2 points], vascular disease, age of 65–74 years, and female gender) was calculated to estimate the stroke risk.17

Study Protocol

Electrocardiography was performed to confirm the presence of AF in each patient. The procedure was explained to each patient, and a written informed consent was obtained. Before BP measurement, upper arm circumferences were measured to allow the correct choice of cuff size. We used 2 automated oscillometric BP monitors, Omron M5-I Professional (Medizintechnik, Mannheim, Germany) and Microlife BPA100 Plus (Microlife, Heerbrugg, Switzerland), according to the manufacturers’ instructions. Both devices have been validated according to the European Society of Hypertension International Protocol or Association for the Advancement of Medical Instrumentation.18–20 Regarding AF detection, the Microlife devices had built-in AF-detecting algorithms, showing the warning symbol on the screen if AF was detected, whereas the Omron devices were conventional automated oscillometric BP monitors. Each patient underwent HR measurement by human counting and 2 automated devices.

Patients sat at a table in a quiet room with adequate resting for 30 minutes before measurement. The protocol is presented in Table 1.

Measurements were separated by 5-minute intervals. Three rounds of measurement were performed to obtain the average HRs. Each measurement of BP was taken in the same arm to ensure consistency and accuracy.

| Data                  | Test device 1 (Omron M5-I) | Test device 2 (Microlife BPA100 plus) |
|-----------------------|---------------------------|--------------------------------------|
| Test procedure        | 5-min interval            | 5-min interval                       |
| Human counting        | 5-min interval            | 5-min interval                       |
| Heartbeats on anterior chest for 1 min | 5-min interval            | 5-min interval                       |
| Test device 2         | 5-min interval            | 5-min interval                       |
| Test device 1 (Omron M5-I) | 5-min interval            | 5-min interval                       |
| Human counting        | 5-min interval            | 5-min interval                       |
| Heartbeats on anterior chest for 1 min | 5-min interval            | 5-min interval                       |

The measurement of BP was taken in the same arm in each step.
Statistical Analysis

The continuous variables are expressed as mean (standard deviation) and/or median (interquartile range), and the categorical variables are expressed as number and percentage. Comparison of HRs between automated devices and human counting was performed by Wilcoxon signed rank test because the numerical value of HR was not normally distributed. The correlation was determined using the Spearman’s rank correlation coefficient (\(\rho\)). The intraclass correlation coefficient and the Bland-Altman plot were used to determine the agreement between measurements from automated devices and human counting. We also performed a subgroup analysis with stratification on manually counted HR greater than or less than 80 bpm.

Results

Totally, 47 patients were enrolled, of which 42 (89%) were detected as having AF by Microlife and 5 (11%) were not. The baseline characteristics of the study subjects are shown in Table 2. Among the 47 enrolled patients, the mean age was 76.2 years, with male dominance (59.5%). The average BP was 146/81 mm Hg. As for the comorbidities, 42.5% of the studied patients had hypertension, 31.9% had diabetes, and 25.5% had hyperlipidemia/smoking status. The average CHA\textsubscript{2}-DS\textsubscript{2}-VASc score was 2.8; 46.8% of the studied patients were prescribed with anticoagulants, and 38.3% were prescribed with aspirin. Regarding HR control, 55.3% of the patients received \(\beta\)-blockers, 34% received digoxin, and 25.5% received calcium channel blockers.

Among the 47 enrolled patients, the mean HR measured by human counting was 80.2 \(\pm\) 10.8 bpm. We found no significant difference in HR measurements between the 2 automated devices and human counting (Omron vs human counting, 81.1 \(\pm\) 11.1 bpm, \(P = .21\); Microlife vs human counting, 81.3 \(\pm\) 10.8 bpm, \(P = .22\)). After stratifying the patients based on human-counting HR greater than or less than 80 bpm, we found higher HRs measured by Microlife in comparison with human counting in patients with human-counting HR greater than 80 bpm (91.1 \(\pm\) 5.2 vs 87.1 \(\pm\) 8.6 bpm, \(P = .034\)) (Table 3).

### Table 2

| Variables                      | All       | AF identified by Microlife | AF not Identified by Microlife |
|-------------------------------|-----------|-----------------------------|--------------------------------|
| Patients, n                   | 47        | 42                          | 5                              |
| Age, mean (SD), y             | 76.2 (9.4)| 75.2 (8.2)                  | 78.3 (7.6)                     |
| Male, %                       | 59.5      | 57.1                        | 80.0                           |
| Blood pressure, mm Hg         | 146/81    | 141/84                      | 151/75                         |
| Human-counting HR             | 80.2 \(\pm\) 10.8 | 79.6 \(\pm\) 11.6          | 90.5 \(\pm\) 10.2               |
| Comorbidities, n (%)          |           |                             |                                |
| CHF                           | 7 (14.8)  | 5 (11.9)                    | 2 (40.0)                       |
| CAD                           | 8 (17.0)  | 7 (16.7)                    | 1 (20.0)                       |
| VHD                           | 6 (12.7)  | 6 (14.3)                    | 0                              |
| HTN                           | 20 (42.5) | 18 (32.9)                   | 2 (40.0)                       |
| PAD                           | 2 (4.2)   | 1 (2.4)                     | 1 (20.0)                       |
| DM                            | 15 (31.9) | 12 (28.6)                   | 3 (60.0)                       |
| Stroke                        | 8 (17.0)  | 8 (9.0)                     | 0                              |
| Hyperlipidemia                | 12 (25.5) | 9 (21.4)                    | 3 (60.0)                       |
| Hyperthyroidism               | 4 (8.5)   | 4 (9.5)                     | 0                              |
| CKD                           | 6 (12.7)  | 4 (9.5)                     | 2 (40.0)                       |
| Smoking                       | 12 (25.5) | 11 (26.2)                   | 1 (20.0)                       |
| Medications, n (%)            |           |                             |                                |
| Aspirin                       | 18 (38.3) | 16 (38.1)                   | 2 (40.0)                       |
| Anticoagulants                | 22 (46.8) | 21 (50)                     | 1 (20.0)                       |
| Amiodarone                    | 3 (6.3)   | 2 (4.8)                     | 1 (20.0)                       |
| Digoxin                       | 16 (34.0) | 14 (33.3)                   | 2 (40.0)                       |
| ACEIs/ARBs                    | 18 (38.3) | 15 (35.7)                   | 3 (60.0)                       |
| \(\alpha\)-Blockers           | 5 (10.6)  | 5 (11.9)                    | 0                              |
| \(\beta\)-Blockers            | 26 (55.3) | 23 (54.8)                   | 3 (60.0)                       |
| CCBs                          | 12 (25.5) | 10 (23.8)                   | 2 (40.0)                       |
| Diuretics                     | 17 (36.1) | 16 (38.1)                   | 1 (20.0)                       |
| Nitrates                      | 6 (12.7)  | 5 (11.9)                    | 1 (20.0)                       |
| OADs                          | 9 (19.1)  | 6 (14.3)                    | 3 (60.0)                       |
| Statins                       | 10 (21.2) | 9 (21.4)                    | 1 (20.0)                       |
| Risk score for stroke         |           |                             |                                |
| CHA\textsubscript{2}-DS\textsubscript{2}-VASc | 2.8       | 2.8                         | 2.9                             |

Abbreviations: ACEIs, angiotensin-converting-enzyme inhibitors; AF, atrial fibrillation; ARBs, angiotensin receptor blockers; CAD, coronary artery disease; CCB, calcium channel blocker; CHF, congestive heart failure; CKD, chronic kidney disease; DM, diabetes mellitus; HTN, hypertension; OAD, oral antidiabetic drug; PAD, peripheral artery disease; VHD, valvular heart disease.
Overall, the Spearman’s rank correlation coefficients ($r$) between the HRs measured by the 2 automated devices and human counting were high (Omron vs human counting, $r = 0.911$; Microlife vs human counting, $r = 0.842$) (Table 4; Figure 1A, B). However, we found a relatively weak correlation between the HRs measured by Microlife device and human counting ($r = 0.538$) in patients with human-counting HR greater than 80 bpm (Table 4 and Figure 1F). Most of the intraclass correlation coefficients between different measurements were higher than 0.85 except in patients with human-counting HR greater than 80 bpm (intraclass correlation coefficient, 0.775) (Table 5). The Bland-Altman plot shows a positive bias of HR indicating an overestimation by Microlife in patients with human-counting HR greater than 80 bpm (Figure 2).

**Discussion**

In this study, we used 2 different automated BP monitors to measure HRs for AF patients. One was Omron, which is one of the most widely used automated BP monitors across Europe and Asia, and the other was Microlife BPA-100, which is equipped with a specific AF detection algorithm. In general, we found a high agreement of HR measurements between the 2 automated BP monitors and human counting in patients with AF. Nevertheless, a relatively weak correlation between HRs measured by Microlife and human counting was noted in patients with human-counting HR greater than 80 bpm. The Microlife BPA-100 automated BP monitor overestimated HRs in AF patients with a higher HR.

With an automated device, patients can measure both their BP and HR. Although investigators have suggested that there was no impact on the accuracy of BP measurement using automated devices in patients with sustained AF, literature regarding the accuracy of HR measured by automated devices was scarce. Vazquez-Rodriguez et al. reported a high correlation between the measurement of HRs by Philips SureSigns VS1 (Philips Medical Systems, Andover, Massachusetts) and a manual method determined by measuring central pulse for 1 minute, either in SR or AF rhythm. Our study showed similar results in that both the Omron and Microlife devices had high consistency with human counting method in HR measurement.

Wiesel et al. developed an algorithm for AF detection, which has been integrated into the Microlife BPA-100. This algorithm can calculate the irregularity index of a patient’s pulse, which is defined as the standard deviation of the time intervals between successive heartbeats divided by the mean of the intervals for the total number of beats analyzed. The average time interval of the last 10 beats, during deflation of cuff, is used for calculation of HRs. However, intervals that are 25% shorter or longer than that of the average are discarded. When patients with AF have a rapid ventricular rate, a heartbeat occurring with a very short time interval after the preceding beat may have a

### Table 3

|               | Mean Values of Heart Rate Measured by Automated Devices and Human Counting |
|---------------|---------------------------------------------------------------------------|
| **Human Counting** | **Omron** | **Automated Devices** | **Microlife** |
| HR, bpm       | HR, bpm | D, bpm$^a$ | $p^b$ | HR, bpm | D, bpm$^a$ | $p^b$ |
| All, mean (SD)| 80.2 (10.8) | 81.1 (11.1) | +0.8 (0.41) | .21 | 81.3 (10.8) | +1.6 (0.58) | .22 |
| Median (IQR)  | 80 (73–86) | 82 (73–87) | | | 82 (75–89) | | |
| Manually measured HR < 80 bpm, n = 22 | | | | | | |
| Mean (SD)     | 71.7 (9.2) | 72.2 (2.5) | +0.5 (0.22) | .18 | 71.6 (7.4) | −0.1 (0.23) | .41 |
| Median (IQR)  | 71 (65–76) | 73 (64–81) | | | 77 (63–81) | | |
| Manually measured HR ≥ 80 bpm, n = 25 | | | | | | |
| Mean (SD)     | 87.1 (8.6) | 88.2 (6.9) | +1.8 (1.51) | .45 | 91.1 (5.2) | +4.2 (2.53) | .034 |
| Median (IQR)  | 85 (80–93) | 86 (82–92) | | | 88 (82–95) | | |

Abbreviations: bpm, beats per minute; HR, heart rate; IQR, interquartile range.

$^a$Difference between automatic devices and human counting.

$^b$Compared with human counting using Wilcoxon signed rank test.

### Table 4

**Spearman’s Rank Correlation Coefficient ($r$) Between Heart Rate Measured by Automated Devices and Human Counting**

|               | All | HR < 80 bpm | HR ≥ 80 bpm |
|---------------|-----|-------------|-------------|
| **Omn and human counting** | 0.911 | .001 | 0.901 | <.001 | 0.764 | .002 |
| **Microlife and human counting** | 0.842 | .015 | 0.805 | .013 | 0.538 | .022 |

Abbreviations: bpm, beats per minute; HR, heart rate.
markedly diminished stroke volume, resulting in no detectable pulse. Therefore, the time interval between heartbeats may be overestimated because of the undetectable pulse between beats. These erroneously measured longer time intervals will then be discarded during calculation of the irregular index and HR. As a result, the calculation algorithm incorporated in the Microlife device may overestimate the HR in AF patients with a higher HR, as observed in our study. Of note, 5 patients in this study with documented AF were missed by the AF detection algorithm. Although this occurred in a small number of patients, this should be examined and validated in a large sample. On the other hand, our analysis showed the sensitivity of the Microlife device as 89.3%, which was much lower than those reported in previous validation studies (sensitivity, 93.9%–98.7%).

However, in the primary care setting, the reported sensitivity of the Microlife device was 83% (95% confidence interval, 63%–95%).

### TABLE 5 Intraclass Correlation Coefficient Between Heart Rate Measured by Automated Devices and Human Counting

|               | All  | HR < 80 bpm | HR ≥ 80 bpm |
|---------------|------|-------------|-------------|
| Omron and human counting | 0.954 | 0.932 | 0.876 |
| Microlife and human counting | 0.912 | 0.881 | 0.775 |

Abbreviations: bpm, beats per minute; HR, heart rate.
Increasing attention has been given to home BP monitoring because it is more closely correlated to ambulatory BP monitoring and more predictive of adverse outcomes. Automated BP monitors have the advantage of minimizing interobserver bias and being convenient to use. In addition, patient self-monitoring of BP at home can improve BP control and compliance.

The importance of AF screening is increasingly being recommended by most cardiovascular societies, particularly for those 65 years or older or stroke survivors. Because hypertension affects up to 90% of patients with AF and the concept of opportunistic screening has evolved, BP machines with AF detection algorithms have become a reasonable and recommended instrument. For patients with persistent AF, rate control is an integral part of treatment that improves AF-related symptoms. The HR targets are classified into the lenient (<110 bpm) and stricter (<80 bpm) rate control targets. Holter 24-hour monitoring has been recommended for assessment of adequacy of HR control. Although the Holter monitor permits the detection of baseline rhythm and HRs during rest, sleeping and ambulation, the bulkiness of the device, and its inconvenience limit its clinical application. Automated home BP monitors could help AF patients provide their HR data for clinical decision-making.

Our study showed 2 important findings. The first one was the high accuracy of 2 automated BP monitors in the measurement of HR, which justified their clinical use for HR recordings in patients with AF. Therefore, clinicians could adjust the dosage of medications for HR control based on the daily HR data from automated BP monitors. The second finding was that the Microlife device seemed to overestimate the HR by nearly 4 bpm compared with human counting in patients with a higher HR. Current guidelines suggest strict HR control
for symptomatic AF patients, recommending a cutoff value of 80 bpm.\textsuperscript{1,2} When symptomatic AF patients provided their daily HR recordings measured by the Microlife devices and the averaged HR was greater than 80 bpm, the interpretation should be made with caution because of the possible overestimation of HR by the Microlife device. Clinicians might have to arrange further continuous ECG monitors, such as Holter monitor or skin patch recorder, to more accurately measure the HR.

**Limitations**

This study has some limitations to be acknowledged. First, the study was limited to HR measurements by Omron M5-I and Microlife BPA-100 plus. Whether the results could be extrapolated to other devices is unknown. Second, only 1 investigator performed human HR counting, as well as the operation of automated devices, and the investigator was not blinded to the results. Third, we assumed that there was little change in HR in the resting state. The human counting and automated measurements were not obtained simultaneously. Fourth, patients with extreme tachycardia (HR > 120 bpm) were not present in our cohort, and the conclusion of this study may not be applied to those patients. Finally, we only included participants whose arm circumferences were appropriate for use of a normal adult-size BP cuff.

**Conclusions**

There is high agreement in HR measurement between a conventional BP monitor (Omron M5-I), AF-detecting BP monitor (Microlife BPA-100), and human counting in the presence of AF. Although being equipped with a specific algorithm for AF detection, the Microlife device overestimated HR in AF patients with a resting HR of more than 80 bpm.

**REFERENCES**

1. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J*. 2016;37(38):2893–2962.
2. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. *Circulation*. 2014;130(23):e199–e267.
3. Carlsson J, Miketic S, Windeler J, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. *J Am Coll Cardiol*. 2003;41(10):1690–1696.
4. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. *N Engl J Med*. 2002;347(23):1825–1833.
5. Parati G, Stergiou GS, Asmar R, et al. European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. *J Hypertens*. 2008;26(8):1505–1526.
6. Pickering TG, Miller NH, Ogedegbe G, et al. Call to action on use and reimbursement for home blood pressure monitoring: executive summary: a joint scientific statement from the American Heart Association, American Society Of Hypertension, and Preventive Cardiovascular Nurses Association. *Hypertension*. 2008;52(1):1–9.
7. Verberk WJ, Omboni S, Kollias A, Stergiou GS. Screening for atrial fibrillation with automated blood pressure measurement: research evidence and practice recommendations. *Int J Cardiol*. 2016;203:465–473.
8. Wiesel J, Wiesel D, Suri R, Messineo FC. The use of a modified sphygmomanometer to detect atrial fibrillation in outpatients. *Pacing Clin Electrophysiol*. 2004;27(5):639–643.
9. Wiesel J, Fitzig L, Herschyan Y, Messineo FC. Detection of atrial fibrillation using a modified microlife blood pressure monitor. *Am J Hypertens*. 2009;22(8):848–852.
10. Stergiou GS, Karpettas N, Protopogerou A, Nasothimiou EG, Kyriakidis M. Diagnostic accuracy of a home blood pressure monitor to detect atrial fibrillation. *J Hum Hypertens*. 2009;23(10):654–658.
11. Bury G, Swan D, Cullen W, et al. Screening for atrial fibrillation in general practice: a national, cross-sectional study of an innovative technology. *Int J Cardiol*. 2015;178:247–252.
12. Ng KG. Automated noninvasive blood pressure measurement. *Intensive Care World*. 1995;12(3):89–102.
13. O’Brien E, Waeber B, Parati G, Staessen J, Myers MG. Blood pressure measuring devices: recommendations of the European Society of Hypertension. *BMJ*. 2001;322(7285):531–536.
14. Pagonas N, Schmidt S, Eysel J, et al. Impact of atrial fibrillation on the accuracy of oscillometric blood pressure monitoring. *Hypertension*. 2013;62(3):579–584.
15. Stergiou GS, Kollias A, Destounis A, Tzamouranis D. Automated blood pressure measurement in atrial fibrillation: a systematic review and meta-analysis. *J Hypertens*. 2012;30(11):2074–2082.
16. Vazquez-Rodriguez B, Pita-Fernandez S, Regueiro-Lopez M, et al. Concordance between automatic and manual recording of blood pressure depending on the absence or presence of atrial fibrillation. *Am J Hypertens*. 2010;23(10):1089–1094.
17. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. *Chest*. 2010;137(2):263–272.
18. El Assaad MA, Topouchian JA, Asmar RG. Evaluation of two devices for self-measurement of blood pressure according to the international protocol: the Omron M5-I and the Omron 705IT. *Blood Press Monit*. 2003;8(3):127–133.
19. Stergiou GS, Giovas PP, Neofytou MS, Adamopoulos DN. Validation of the Microlife BPA100 Plus device for self-home blood pressure measurement according to the International Protocol. *Blood Press Monit*. 2006;11(3):157–160.
20. Belghazi J, El Feghali RN, Moussalem T, Reidych M, Asmar RG. Validation of four automatic devices for self-measurement...
Measurements of Heart Rate in Atrial Fibrillation

of blood pressure according to the International Protocol of the European Society of Hypertension. 

21. Anastas ZM, Jimerson E, Garolis S. Comparison of non-invasive blood pressure measurements in patients with atrial fibrillation. J Cardiovasc Nurs. 2008;23(6):519–524.

22. Farsky S, Benova K, Krausova D, Sirotiakova J, Vysocanova P. Clinical blood pressure measurement verification when comparing a Tensival duo control device with a mercury sphygmomanometer in patients suffering from atrial fibrillation. Blood Press Monit. 2011;16(5):252–257.

23. Kearley K, Selwood M, Van den Bruel A, et al. Triage tests for identifying atrial fibrillation in primary care: a diagnostic accuracy study comparing single-lead ECG and modified BP monitors. BMJ Open. 2014;4(5):e004565.

24. Chan PH, Wong CK, Pun L, et al. Head-to-head comparison of the AliveCor heart monitor and Microlife WatchBP Office AFIB for atrial fibrillation screening in a primary care setting. Circulation. 2017;135(1):110–112.

25. Verberk WJ, Kroon AA, Kessels AG, de Leeuw PW. Home blood pressure measurement: a systematic review. J Am Coll Cardiol. 2005;46(5):743–751.

26. Asayama K, Ohkubo T, Kikuya M, et al. Prediction of stroke by self-measurement of blood pressure at home versus casual screening blood pressure measurement in relation to the Joint National Committee 7 classification: the Ohasama study. Stroke. 2004;35(10):2356–2361.

27. Agarwal R, Andersen MJ. Prognostic importance of ambulatory blood pressure recordings in patients with chronic kidney disease. Kidney Int. 2006;69(7):1175–1180.

28. Niiranen TJ, Hanninen MR, Johansson J, Reunanen A, Jula AM. Home-measured blood pressure is a stronger predictor of cardiovascular risk than office blood pressure: the Finn-Home study. Hypertension. 2010;55(6):1346–1351.

29. Uhlig K, Patel K, Ip S, Kitsios GD, Balk EM. Self-measured blood pressure monitoring in the management of hypertension: a systematic review and meta-analysis. Ann Intern Med. 2013;159(3):185–194.